Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
12 nov 2015 - 22:00
Statutaire naam
Galapagos NV
Titel
Galapagos reports third quarter 2015 cash position of €374 M
Bericht
• Financial results of the first nine months:
o Group revenues €47.2 M
o Group net loss €61.4 M, reflecting planned increase in pipeline investment
o End of third quarter cash €374.4 M, including €7.9 M in restricted cash
• Filgotinib 24 week DARWIN Phase 2B studies successful
o Confirmed promising efficacy and differentiated safety profile
o Galapagos regained full rights, in discussions with multiple potential partners
o Preparations underway for Phase 3 program in rheumatoid arthritis
o Phase 2 FITZROY 10 week topline readout expected in Crohn's disease before year-end
• Nomination of cystic fibrosis candidate GLPG2665 completes discovery phase of triple combination therapy. Clinical trial initiations expected before year-end
Datum laatste update: 07 februari 2025